* If you want to update the article please login/register
"In particular, gay and bisexual males in Australia have increased incidences of bacterial STIs in the last decade. " Although STIs are simple to identify and treatment is effective, untreated STIs can lead to significant health issues. Previous studies have found that taking two100 mg oxycycline tablets within 24 hours of sex as prophylaxis reduces syphilis and chlamydia dramatically. Hence, the question of whether or not taking doxycycline daily in a high risk group has raised the incidence of STIs. We designed this study as a non-randomized observational cohort trial comparing before and after measurements to see if taking 100mg doxycycline daily would help young gay and bisexual men avoid gonorrhoea, syphilis, and chlamydia. Our key goals are to: assess the acceptability of a daily dosing regimen for doxycycline prophylaxis, and determine the safety of 100 mg of doxycycline STI prophylaxis against reinfection with gonorrhoea, chlamydia, and syphilis.
Source link: https://clinicaltrials.gov/ct2/show/NCT03709459
"The frequency of Chlamydia trachomatis and Neisseria gonorrhoea coinfection can vary based on their individual prevalence and prevalence rates. " Ceftriaxone is particularly effective against prone N. gonorrhoeae. These doses of ceftriaxone are higher than previously recommended due to fears regarding increased gonococcal minimum inhibitory concentrations around the world. Cefixime is the only injectable cephalosporin that can be used for gonococcal therapy if an injectable cephalosporin is not available, and it is the only oral cephalosporin that can be used for gonococcal therapy. In nonpregnant people with gonococcal disease, Doxycycline was approved for presumptive treatment of chlamydia. The aim of the study is to determine the safety of two regimens when mixed with doxycycline with cefixime or ceftriaxone.
Source link: https://clinicaltrials.gov/ct2/show/NCT05216744
"Women who have had a urogenital chlamydia or gonorrhea infection at any time during the 16 weeks leading up to enrollment in the school visit, with one or two risk factors present, or those with one or two risk factors will be enrolled. ".
Source link: https://clinicaltrials.gov/ct2/show/NCT04553068
"All participants in the active groups will receive three IM injections of the adjuvanted CTH522 and some will receive the non-adjuvanted CTH522 by mail or ID. CTH522-CAF01, the 85-Bcg CTH522-CAF01 and Cohort A will get three IM vaccinations of 85-Bcg CTH522-CAF1. A1 will receive ID placebo on Day 28 + Day 112, and TO placebo on Day 140; A2 will receive TO placebo at Day 258 and non-adjudvanted to CTH522 at Day 140. The 85-Bcg CTH522-CAF01 will be the first IM vaccinations of 85 u03bcg CTH522-CAF01. B1 and 112 will receive TO vaccination of the non-adjudvanted CTH522 on Day 28 and 112 and TO placebo at Day 140, while B2 and the same on Day 28 and 112 will be vaccinated, while B2 will receive the same for Day 28 and 112, but non-adjudvanted to a CTH522 boost at Day 140. The CTH52-CAF01, a bcg CTH52-CAF01, will have three IM vaccinations for 85 bcg CTH522-CAF01. At Day 28, C1 will get ID vaccination of the non-adjuvanted 24 bcg CTH522 in both day 28 and 112 and TO placebo, while C2 will get the same for Day 28 and 112, but TO 12 – a factor of CTH522 in each eye at Day 140. The Cohort D will be given three IM vaccinations, which will be CTH522-CAF01. The aim of the two IM CTH522 doses on the immunogenicity results is to investigate the implications of the two IM CTH522 doses on the immunogenicity results. "Tu03bcg CTH522-CAF09b" is the newest CEF vaccination scheme in 85. b. cg CTH522-CAF09b. ".
Source link: https://clinicaltrials.gov/ct2/show/NCT03926728
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions